FDA Approves New Type Of Medication For ADHD

The U.S. Food and Drug Administration (FDA) approved a new type of medication for attention-deficit/hyperactivity disorder (ADHD) developed by Otsuka. The medication, called Simtriyo (centanafadine), inhibits reuptake of three neurotransmitters (norepinephrine, dopamine, and serotonin) and is formulated as an extended-release capsule for children ages 6 and older and adults to be taken once daily. The three neurotransmitters are involved in the ability to pay attention and to regulate behavior. By inhibiting reuptake, the medication increases the availability of these neurotransmitters and improves attention and behavioral regulation.

The medication is considered a stimulant and must be scheduled . . .